{"id":"NCT01300351","sponsor":"AstraZeneca","briefTitle":"Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women","officialTitle":"A Randomised, Double-Blind, Parallel-Group, Multicentre Study Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With ER+ Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03","primaryCompletion":"2014-03","completion":"2014-03","firstPosted":"2011-02-21","resultsPosted":"2015-04-24","lastUpdate":"2015-04-24"},"enrollment":249,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Fulvestrant","otherNames":["Faslodex"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Fulvestrant 500mg","type":"EXPERIMENTAL"},{"label":"Fulvestrant 250mg","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy of a new dose of 500mg Fulvestrant with the standard dose of 250mg in Chinese postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed a prior endocrine treatment.","primaryOutcome":{"measure":"Progression-free Survival","timeFrame":"36 months","effectByArm":[{"arm":"Fulvestrant 500 mg","deltaMin":8,"sd":null},{"arm":"Fulvestrant 250 mg","deltaMin":4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.078"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":15,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=593&filename=D6997L00021_CSR_Synopsis.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":109},"commonTop":["INJECTION SITE REACTION","INJECTION SITE PAIN","PYREXIA","FATIGUE","NAUSEA"]}}